

Michel P Hermans

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3184255/publications.pdf>

Version: 2024-02-01

114
papers

4,671
citations

212478

28
h-index

124990

64
g-index

116
all docs

116
docs citations

116
times ranked

7824
citing authors

#	ARTICLE	IF	CITATIONS
1	Assessment of Clinical Outcomes Among Children and Adolescents Hospitalized With COVID-19 in 6 Sub-Saharan African Countries. <i>JAMA Pediatrics</i> , 2022, 176, e216436.	3.3	44
2	Lipid and cardiometabolic features of T2DM patients achieving stricter LDL-C and non-HDL-C targets in accordance with ESC/EAS 2019 guidelines. <i>Acta Cardiologica</i> , 2021, 76, 375-383.	0.3	2
3	Epidemiology of acutely decompensated systolic heart failure over the 2003â€“2013 decade in Douala General Hospital, Cameroon. <i>ESC Heart Failure</i> , 2021, 8, 481-488.	1.4	4
4	Clinical characteristics and short-term prognosis of in-patients with diabetes and COVID-19: A retrospective study from an academic center in Belgium. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2021, 15, 149-157.	1.8	26
5	Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARMÎ±) in the Metabolic Syndrome: Is Pemafibrate Light at the End of the Tunnel?. <i>Current Atherosclerosis Reports</i> , 2021, 23, 3.	2.0	18
6	The Critical Need for Pooled Data on Coronavirus Disease 2019 in African Children: An AFREhealth Call for Action Through Multicountry Research Collaboration. <i>Clinical Infectious Diseases</i> , 2021, 73, 1913-1919.	2.9	14
7	Severe acute malnutrition in childhood, chronic diseases, and human capital in adulthood in the Democratic Republic of Congo: the Lwiro Cohort Study. <i>American Journal of Clinical Nutrition</i> , 2021, 114, 70-79.	2.2	13
8	Association between severe acute malnutrition during childhood and blood pressure during adulthood in the eastern Democratic Republic of the Congo: the Lwiro cohort study. <i>BMC Public Health</i> , 2021, 21, 847.	1.2	8
9	Impact of rural versus urban setting on kidney markers: a cross-sectional study in South-Kivu, DR Congo. <i>BMC Nephrology</i> , 2021, 22, 234.	0.8	2
10	Body composition of adults with a history of severe acute malnutrition during childhood using the deuterium dilution method in eastern DR Congo: the Lwiro Cohort Study. <i>American Journal of Clinical Nutrition</i> , 2021, 114, 2052-2059.	2.2	6
11	Clinical and biochemical characteristics and analysis of risk factors for euglycaemic diabetic ketoacidosis in type 2 diabetic individuals treated with SGLT2 inhibitors: A review of 72 cases over a 4.5-year period. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2021, 15, 102275.	1.8	17
12	Lipoprotein(a) levels are doubled in left-handed patients with diabetes. <i>Diabetes and Metabolism</i> , 2020, 46, 169-172.	1.4	4
13	â€œMind the gap pleaseâ€“ estimated vs. measured A1c from continuous measurement of interstitial glucose over a 3-month period in patients with type 1 diabetes. <i>Acta Clinica Belgica</i> , 2020, 75, 109-115.	0.5	12
14	Lipohypertrophy Effect on Glycemic Profile in an Adult With Type 1 Diabetes Using Scanned Continuous Glucose Monitoring. <i>Journal of Diabetes Science and Technology</i> , 2020, 14, 500-501.	1.3	5
15	Prevalence and determinants of blood pressure variability in pygmies of Southern region Cameroon. <i>Journal of Hypertension</i> , 2020, 38, 2198-2204.	0.3	3
16	Prevalence and Risk Factors of CKD in South Kivu, Democratic Republic of Congo: A Large-Scale Population Study. <i>Kidney International Reports</i> , 2020, 5, 1251-1260.	0.4	10
17	Established and novel gender dimorphisms in type 2 diabetes mellitus: Insights from a multiethnic cohort. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2020, 14, 1503-1509.	1.8	2
18	Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARMÎ±): New Opportunities to Reduce Residual Cardiovascular Risk in Chronic Kidney Disease?. <i>Current Atherosclerosis Reports</i> , 2020, 22, 43.	2.0	8

#	ARTICLE	IF	CITATIONS
19	Supplementation Effect of a Combination of Olive (<i>Olea europea</i> L.) Leaf and Fruit Extracts in the Clinical Management of Hypertension and Metabolic Syndrome. <i>Antioxidants</i> , 2020, 9, 872.	2.2	16
20	COVID-19 in diabetic patients: Related risks and specifics of management. <i>Annales D'Endocrinologie</i> , 2020, 81, 101-109.	0.6	65
21	Euglycemic diabetic ketoacidosis in a patient with type 1 diabetes and SARS-CoV-2 pneumonia: case report and review of the literature. <i>Acta Clinica Belgica</i> , 2020, , 1-5.	0.5	24
22	Clinical Characteristics and Outcomes of Patients Hospitalized for COVID-19 in Africa: Early Insights from the Democratic Republic of the Congo. <i>American Journal of Tropical Medicine and Hygiene</i> , 2020, 103, 2419-2428.	0.6	87
23	Crossing family histories of diabetes and cardiovascular disease leads to unexpected outcomes in diabetic offspring. <i>Journal of Diabetes</i> , 2019, 11, 301-308.	0.8	4
24	Increased CRP: An extended biomarker of microvascular risk in men with type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2019, 33, 107413.	1.2	17
25	Anthropometric and cardiometabolic correlates of prostate volume among diabetic and non-diabetic subjects in South-Kivu. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2019, 13, 350-355.	1.8	1
26	The selective peroxisome proliferator-activated receptor alpha modulator (SPPARM α) paradigm: conceptual framework and therapeutic potential. <i>Cardiovascular Diabetology</i> , 2019, 18, 71.	2.7	104
27	Metabolic syndrome components and prostatic hyperplasia among diabetic and non-diabetic men in the Eastern DR Congo: A cross-sectional study. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2019, 13, 776-780.	1.8	0
28	Frequency and predictors of cholesterol target attainment in patients with stable coronary heart disease in Belgium: results from the Dyslipidemia International Study II (DYSIS II _{CHD}). <i>Acta Clinica Belgica</i> , 2019, 74, 399-404.	0.5	4
29	High rates of atherogenic dyslipidemia, β -cell function loss, and microangiopathy among Turkish migrants with T2DM. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2019, 13, 716-720.	1.8	4
30	Effect of Continuous Glucose Monitoring on Glycemic Control, Acute Admissions, and Quality of Life: A Real-World Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 1224-1232.	1.8	125
31	Elevated triglycerides and low high-density lipoprotein cholesterol level as marker of very high risk in type 2 diabetes. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2018, 25, 118-129.	1.2	30
32	Prevalence, awareness, treatment, and control of hypertension among rural and urban dwellers of the Far North Region of Cameroon. <i>Journal of Hypertension</i> , 2018, 36, 159-168.	0.3	14
33	Prevalence and co-prevalence of comorbidities in Belgian patients with type 2 diabetes mellitus: a transversal, descriptive study. <i>Acta Clinica Belgica</i> , 2018, 73, 68-74.	0.5	14
34	[HDL β /apoA β]: A multivessel cardiometabolic risk marker in women with T2DM. <i>Diabetes/Metabolism Research and Reviews</i> , 2018, 34, e2950.	1.7	4
35	Arterial stiffness and cardiometabolic phenotype of Cameroonian Pygmies and Bantus. <i>Journal of Hypertension</i> , 2018, 36, 520-527.	0.3	6
36	Arterial stiffness in black African ancestry patients with chronic kidney disease living in Cameroon. <i>Cardiovascular Diagnosis and Therapy</i> , 2018, 8, 450-459.	0.7	1

#	ARTICLE	IF	CITATIONS
37	A Belgian consensus strategy to identify familial hypercholesterolaemia in the coronary care unit and its subsequent cascade screening and treatment: BEL-FaHST (The BELgium Familial) Tj ETQq1 1 0.784314 rgBT /Overlock 10 of 50 737		
38	Predictors of LDL-cholesterol target value attainment differ in acute and chronic coronary heart disease patients: Results from DYSIS II Europe. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 1966-1976.	0.8	50
39	Glucose homeostasis abnormalities among Cameroon patients with newly diagnosed hypertension. <i>Journal of Clinical Hypertension</i> , 2017, 19, 519-523.	1.0	6
40	An unusual cause of epidemic thyrotoxicosis. <i>Acta Clinica Belgica</i> , 2017, 72, 451-453.	0.5	4
41	Efficacy and safety of a combination of red yeast rice and olive extract in hypercholesterolemic patients with and without statin-associated myalgia. <i>Complementary Therapies in Medicine</i> , 2017, 35, 140-144.	1.3	12
42	Size, density and cholesterol load of HDL predict microangiopathy, coronary artery disease and β -cell function in men with T2DM. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2017, 11, 125-131.	1.8	18
43	A purified membrane protein from <i>Akkermansia muciniphila</i> or the pasteurized bacterium improves metabolism in obese and diabetic mice. <i>Nature Medicine</i> , 2017, 23, 107-113.	15.2	1,451
44	The mixed benefit of low lipoprotein(a) in type 2 diabetes. <i>Lipids in Health and Disease</i> , 2017, 16, 171.	1.2	20
45	Suboptimal Control of Lipid Levels: Results from 29 Countries Participating in the Centralized Pan-Regional Surveys on the Undertreatment of Hypercholesterolaemia (CEPHEUS). <i>Journal of Atherosclerosis and Thrombosis</i> , 2016, 23, 567-587.	0.9	52
46	Can an electronic glycaemic notebook associated with an insulin calculator improve HbA _{1c} in diabetic patients on a multiple insulin injections regimen? A 26-week observational real-life study. <i>Acta Clinica Belgica</i> , 2016, 71, 51-56.	0.5	0
47	How to transform a metabolic syndrome score into an insulin sensitivity value?. <i>Diabetes/Metabolism Research and Reviews</i> , 2016, 32, 87-94.	1.7	8
48	Sftl-1 in heart failure: relation with disease severity and biomarkers. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2016, 76, 411-416.	0.6	16
49	The normal-weight type 2 diabetes phenotype revisited. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2016, 10, S82-S88.	1.8	15
50	Baseline diabetes as a way to predict CV outcomes in a lipid-modifying trial: a meta-analysis of 330,376 patients from 47 landmark studies. <i>Cardiovascular Diabetology</i> , 2015, 14, 60.	2.7	3
51	Clinical inertia in general practice, a matter of debate: a qualitative study with 114 general practitioners in Belgium. <i>BMC Family Practice</i> , 2015, 16, 13.	2.9	18
52	Bioelectrical impedance outperforms waist circumference for predicting cardiometabolic risk in Congolese hypertensive subjects: a cross-sectional study. <i>BMC Cardiovascular Disorders</i> , 2015, 15, 17.	0.7	5
53	Factors associated with clinical inertia: an integrative review. <i>Advances in Medical Education and Practice</i> , 2014, 5, 141.	0.7	84
54	Association Between Plasma Triglycerides and High-Density Lipoprotein Cholesterol and Microvascular Kidney Disease and Retinopathy in Type 2 Diabetes Mellitus. <i>Circulation</i> , 2014, 129, 999-1008.	1.6	197

#	ARTICLE	IF	CITATIONS
55	Residual macrovascular risk in 2013: what have we learned?. <i>Cardiovascular Diabetology</i> , 2014, 13, 26.	2.7	149
56	What are the characteristics of phenotypic type 2 diabetic patients with low-titer GAD65 antibodies?. <i>Acta Diabetologica</i> , 2014, 51, 103-111.	1.2	8
57	Novel determinants preventing achievement of major cardiovascular targets in type 2 diabetes. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2014, 8, 145-151.	1.8	17
58	Novel unbiased equations to calculate triglyceride-rich lipoprotein cholesterol from routine non-fasting lipids. <i>Cardiovascular Diabetology</i> , 2014, 13, 56.	2.7	15
59	Novel sexual dimorphisms of sleep apnea syndrome in diabetes. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2014, 8, 36-44.	1.8	12
60	Parental brevity linked to cardiometabolic risk in diabetic descendants. <i>Journal of Diabetes and Its Complications</i> , 2014, 28, 141-146.	1.2	0
61	Cardiovascular risk factors: Belgian target achievement. <i>Acta Cardiologica</i> , 2014, 69, 473-481.	0.3	6
62	Residual Microvascular Risk in Type 2 Diabetes in 2014: Is it Time for a Re-Think? A Perspective from the Residual Risk Reduction Initiative (R3i). <i>Journal of Diabetes & Metabolism</i> , 2014, 05, .	0.2	5
63	Discriminant ratio and biometrical equivalence of measured vs. calculated apolipoprotein B100 in patients with T2DM. <i>Cardiovascular Diabetology</i> , 2013, 12, 39.	2.7	7
64	What is the phenotype of patients with gastrointestinal intolerance to metformin?. <i>Diabetes and Metabolism</i> , 2013, 39, 322-329.	1.4	11
65	Sleep apnoea syndrome and 10-year cardiovascular risk in females with type 2 diabetes: relationship with insulin secretion and insulin resistance. <i>Diabetes/Metabolism Research and Reviews</i> , 2013, 29, 227-234.	1.7	45
66	Optimal type 2 diabetes mellitus management: the randomised controlled OPTIMISE benchmarking study: baseline results from six European countries. <i>European Journal of Preventive Cardiology</i> , 2013, 20, 1095-1105.	0.8	25
67	Benchmarking Is Associated With Improved Quality of Care in Type 2 Diabetes. <i>Diabetes Care</i> , 2013, 36, 3388-3395.	4.3	46
68	Increased burden and severity of metabolic syndrome and arterial stiffness in treatment-naïve HIV+ patients from Cameroon. <i>Vascular Health and Risk Management</i> , 2013, 9, 509.	1.0	50
69	Effects of saxagliptin added to sub-maximal doses of metformin compared with uptitration of metformin in type 2 diabetes: the PROMPT study. <i>Current Medical Research and Opinion</i> , 2012, 28, 1635-1645.	0.9	27
70	Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levels. <i>Journal of Clinical Lipidology</i> , 2012, 6, 434-442.	0.6	24
71	The atherogenic dyslipidemia ratio [log(TG)/HDL-C] is associated with residual vascular risk, beta-cell function loss and microangiopathy in type 2 diabetes females. <i>Lipids in Health and Disease</i> , 2012, 11, 132.	1.2	66
72	The multi-faceted outcomes of conjunct diabetes and cardiovascular familial history in type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2012, 26, 187-194.	1.2	8

#	ARTICLE	IF	CITATIONS
73	eNOS [Glu298Asp] polymorphism, erectile function and ocular pressure in type 2 diabetes. <i>European Journal of Clinical Investigation</i> , 2012, 42, 729-737.	1.7	14
74	Statin therapy and cataract in type 2 diabetes. <i>Diabetes and Metabolism</i> , 2011, 37, 139-143.	1.4	19
75	Non-HDL-cholesterol as valid surrogate to apolipoprotein B100 measurement in diabetes: Discriminant Ratio and unbiased equivalence. <i>Cardiovascular Diabetology</i> , 2011, 10, 20.	2.7	54
76	Study rationale and design of OPTIMISE, a randomised controlled trial on the effect of benchmarking on quality of care in type 2 diabetes mellitus. <i>Cardiovascular Diabetology</i> , 2011, 10, 82.	2.7	12
77	Non-invited Review: Prevention of microvascular diabetic complications by fenofibrate: lessons from FIELD and ACCORD. <i>Diabetes and Vascular Disease Research</i> , 2011, 8, 180-189.	0.9	30
78	Reducing vascular events risk in patients with dyslipidaemia: an update for clinicians. <i>Therapeutic Advances in Chronic Disease</i> , 2011, 2, 307-323.	1.1	16
79	Impact of Fenofibrate on Type 2 Diabetes Patients with Features of the Metabolic Syndrome: Subgroup Analysis From FIELD. <i>Current Cardiology Reviews</i> , 2010, 6, 112-118.	0.6	21
80	log(TG)/HDL-C is related to both residual cardiometabolic risk and β -cell function loss in type 2 diabetes males. <i>Cardiovascular Diabetology</i> , 2010, 9, 88.	2.7	67
81	Reducing residual vascular risk in patients with atherogenic dyslipidemia: where do we go from here?. <i>Clinical Lipidology</i> , 2010, 5, 811-826.	0.4	23
82	Centralized Pan-European survey on the under-treatment of hypercholesterolaemia (CEPHEUS): overall findings from eight countries. <i>Current Medical Research and Opinion</i> , 2010, 26, 445-454.	0.9	66
83	Impact of metabolic syndrome and its severity on microvascular complications in type 2 diabetes. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2010, 4, 150-154.	1.8	16
84	The elusive type 2 diabetes individual achieving tight blood pressure target: A phenotypic study. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2010, 4, 215-219.	1.8	3
85	Dietary cassava, β -cell function and hyperbolic product loss rate in type 2 diabetes patients from South Kivu. <i>Diabetes and Metabolism</i> , 2010, 36, 108-113.	1.4	6
86	Implications of the ACCORD Lipid study: perspective from the Residual Risk Reduction Initiative ($R^2 > 3$). <i>Current Medical Research and Opinion</i> , 2010, 26, 1793-1797.	0.9	46
87	Raised natriuretic peptides, Big-endothelin-1 and improved beta-cell function in type 2 diabetic males with hyperuricaemia. <i>Diabetes and Vascular Disease Research</i> , 2009, 6, 190-193.	0.9	8
88	Quality of life and efficacy of nebivolol in an open-label study in hypertensive patients. The QoLaN study. <i>Blood Pressure</i> , 2009, 18, 5-14.	0.7	5
89	Erectile dysfunction, microangiopathy and UKPDS risk in type 2 diabetes. <i>Diabetes and Metabolism</i> , 2009, 35, 484-489.	1.4	38
90	Cardiometabolic phenotype and UKPDS risk in male type 2 diabetic patients with obstructive sleep apnoea. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2009, 3, 50-54.	1.8	14

#	ARTICLE	IF	CITATIONS
91	Switch from metformin monotherapy to bitherapy with metformin and repaglinide to achieve glycated haemoglobin target in type 2 diabetes (REPAMET Study). <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2009, 3, 224-227.	1.8	2
92	Centralized Pan-european Survey on the Undertreatment of Hypercholesterolemia (CEPHEUS). <i>Acta Cardiologica</i> , 2009, 64, 177-185.	0.3	13
93	Quality of life and efficacy of nebivolol in an open-label study in hypertensive patients. the QoLaN study. <i>Blood Pressure Supplement</i> , 2009, 1, 5-14.	0.2	1
94	Title page. <i>American Journal of Cardiology</i> , 2008, 102, i.	0.7	103
95	The Residual Risk Reduction Initiative: A Call to Action to Reduce Residual Vascular Risk in Patients with Dyslipidemia. <i>American Journal of Cardiology</i> , 2008, 102, 1K-34K.	0.7	371
96	Metabolic syndrome in Bantu subjects with type 2 diabetes from sub-Saharan extraction. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2008, 2, 5-11.	1.8	26
97	Neurohormonal biomarkers and UKPDS stroke risk in type 2 diabetic women on primary cardiovascular prevention. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2008, 2, 93-98.	1.8	8
98	Phenotypic characterization of first generation Maghrebien migrants with type 2 diabetes. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2008, 2, 115-124.	1.8	38
99	Belonging to a diabetes patients' association is predictive of better metabolic control. <i>Diabetes and Metabolism</i> , 2008, 34, 279-282.	1.4	5
100	The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients. <i>Diabetes and Vascular Disease Research</i> , 2008, 5, 319-335.	0.9	227
101	Glucose Homeostasis and Genotype-Phenotype Interplay in Cystic Fibrosis Patients With CFTR Gene ΔF508 Mutation. <i>Diabetes Care</i> , 2007, 30, 1187-1192.	4.3	35
102	DIABETES AND THE ENDOTHELIUM. <i>Acta Clinica Belgica</i> , 2007, 62, 97-101.	0.5	30
103	Diabetic macro- and microvascular disease in type 2 diabetes. <i>Diabetes and Vascular Disease Research</i> , 2007, 4, S7-S11.	0.9	30
104	The non-HDL-C/HDL-C ratio provides cardiovascular risk stratification similar to the ApoB/ApoA1 ratio in diabetics: Comparison with reference lipid markers. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2007, 1, 23-28.	1.8	12
105	The metabolic syndrome phenotype is associated with raised circulating Big endothelin-1 independently of coronary artery disease in type 2 diabetes. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2007, 1, 229-237.	1.8	10
106	METABOLIC (GLYCAEMIC, LIPIDIC) AND BLOOD PRESSURE CONTROL IN 101 TYPE 2 DIABETIC PATIENTS ON FIRST ADMISSION TO DIABETES CENTRES. <i>Acta Clinica Belgica</i> , 2006, 61, 127-133.	0.5	1
107	Prevalence and Determinants of Impaired Glucose Metabolism in Frail Elderly Patients: The Belgian Elderly Diabetes Survey (BEDS). <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2005, 60, 241-247.	1.7	18
108	NON-PHARMACOLOGICAL MANAGEMENT OF TYPE 2 DIABETES. <i>Acta Clinica Belgica</i> , 2004, 59, 14-19.	0.5	11

#	ARTICLE	IF	CITATIONS
109	Comparative performance of serum cystatin-c versus serum creatinine in diabetic subjects. <i>Diabetes and Metabolism</i> , 2003, 29, 377-383.	1.4	18
110	HOMA-modelling of insulin sensitivity and β -cell function in anorexia nervosa. <i>European Eating Disorders Review</i> , 2002, 10, 41-50.	2.3	8
111	Insulin Lispro (Humalog [®]), A Novel Fast-Acting Insulin Analogue For The Treatment Of Diabetes Mellitus: Overview Of Pharmacological And Clinical Data. <i>Acta Clinica Belgica</i> , 1999, 54, 233-240.	0.5	5
112	Insulin Lispro (Humalog [®]) In The Treatment Of Diabetes Mellitus: Overview Of Belgian Clinical Data From Global Studies. <i>Acta Clinica Belgica</i> , 1999, 54, 241-245.	0.5	2
113	Glycaemic and Blood Pressure Controls Achieved in A Cohort of 318 Patients with Type 2 Diabetes. <i>Acta Clinica Belgica</i> , 1999, 54, 328-333.	0.5	10
114	Insulin release has no absolute requirement for extracellular monovalent ions. <i>FEBS Letters</i> , 1986, 201, 173-176.	1.3	2